All Insurance Covered
( Cashless / Reimbursement )
Tirzepatide (Mounjaro) for Weight Loss
Tirzepatide is a next-generation injectable medication developed by Eli Lilly and Company. It has recently been approved by India’s Central Drugs Standard Control Organisation (CDSCO) for the treatment of Type 2 diabetes and chronic weight management. In India, it is marketed under the brand name Mounjaro, while internationally, it is also known as Zepbound for weight loss applications.
What Is Tirzepatide?
Tirzepatide is a once-weekly subcutaneous injection that activates two key hormones:
- GIP (Glucose-Dependent Insulinotropic Polypeptide)
- GLP-1 (Glucagon-Like Peptide-1)
These hormones regulate blood sugar levels, appetite, and energy balance. By targeting both, Tirzepatide offers a dual mechanism that enhances insulin response and supports sustainable weight loss.
Neat & Clean Rooms
Spotlessly clean, profoundly caring. Our hospital ensures a pristine environment for your well-being
Modern Equiments
Our hospital has advanced technology gadgets and the best equipment in every field.
City Centre Location
Conveniently located at the heart of the city, our hospital offers easy access and exceptional care in a prime city center location
Tirzepatide for Weight Loss
Clinical studies have shown that Tirzepatide leads to significant weight reduction without requiring extreme dietary changes or intensive exercise. It works by:
- Suppressing appetite
- Enhancing fat metabolism
- Reducing food cravings
In comparative trials, Tirzepatide has demonstrated superior results to Semaglutide (used in Ozempic and Wegovy) in both weight loss and glycemic control, contributing to its growing adoption among healthcare professionals.
Key Benefits of Tirzepatide
- Non-surgical alternative: Offers a medically supervised option for individuals seeking weight loss without surgery.
- Clinically proven results: Patients have reported an average weight loss of 15% or more over several months.
- Convenient dosing: Requires only one injection per week, improving treatment adherence.
- Cardiometabolic improvements: Supports insulin sensitivity and contributes to better cardiovascular health.
Dosage and Administration
Tirzepatide is available as a pre-filled injection pen for subcutaneous use.
- Starting dose: 2.5 mg once weekly
- Titration: May be increased to 5 mg, 10 mg, or higher based on individual tolerance and physician guidance
It can be administered with or without food, ideally on the same day each week. Tirzepatide should always be used under medical supervision.
Mechanism of Action
Tirzepatide supports metabolic health through the following mechanisms:
- Enhances insulin secretion in response to elevated blood glucose
- Slows gastric emptying, promoting satiety
- Reduces appetite and caloric intake, aiding weight loss
